Crossmark

A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

Crossref DOI link: https://doi.org/10.1038/s41467-025-60394-0

Published Online: 2025-06-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mazziotta, Francesco

Martin, Lauren E.

Egan, Daniel N.

Bar, Merav

Kinsella, Sinéad

Paulson, Kelly G.

Voillet, Valentin https://orcid.org/0000-0002-5751-3881
Lahman, Miranda C.

Hunter, Daniel

Schmitt, Thomas M.

Duerkopp, Natalie

Yeung, Cecilia C. S. https://orcid.org/0000-0001-6799-2022
Tang, Tzu-Hao https://orcid.org/0009-0009-2596-1872
Gottardo, Raphael https://orcid.org/0000-0002-3867-0232
Asano, Yuta

Wilcox, Elise C.

Lee, Bo

Zhang, Tianzi

Lopedote, Paolo

Penter, Livius https://orcid.org/0000-0002-9060-0207
Wu, Catherine J.

Milano, Filippo

Greenberg, Philip D.

Chapuis, Aude G. https://orcid.org/0000-0002-9574-5448
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (5K08CA169485)

Fred Hutchinson Cancer Research Center (n/a)

Damon Runyon Cancer Research Foundation (n/a)

Gabrielle's Angel Foundation for Cancer Research (n/a)

V Foundation for Cancer Research (n/a)

the Guillot Family ZachAttacksLeukemia Foundation, Parker Institute for Cancer Immunotherapy
License Information

Text and Data Mining valid from 2025-06-05

Version of Record valid from 2025-06-05
More Information

Article History

Received: 31 March 2025

Accepted: 21 May 2025

First Online: 5 June 2025

Competing interests

: A.G.C. has received support from Juno Therapeutics, Lonza, and Affini-T. P.D.G. is a consultant, has received support from and has had ownership interest in Juno Therapeutics and Affini-T Therapeutics. He has also received support from Lonza, and consults and has ownership interest in Rapt Therapeutics, Elpiscience, Immunoscape, Earli, Metagenomi. Catalia, and Nextech. P.D.G., T.M.S., and the Fred Hutchinson Cancer Research Center have intellectual property related to TCRC4. A.G.C. and K.G.P. have received reagents from 10X Genomics. R.G. has received consulting income from Takeda, Arcellx and Sanofi, and declares ownership in Ozette Technologies. CJW receives equity from BionTech, and is a SAB member of Repertoire, Adventris, Aethon Therapeutics and Nature’s Toolbox. M.B. is employed at Bristol Myers Squibb. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below